Lisdexamfetamine Dimesylate in Residual Symptoms and Cognitive Impairment in Major Depressive Disorder.
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
This study aims to test the effect of a newly-approved stimulant medication, lisdexamfetamine
dimesylate (Vyvanse), on specific residual symptoms of depression found in some patients who
are undergoing treatment with, but have only partially responded to, a selective-serotonin
reuptake inhibitor (SSRI) or selective-norepinephrine reuptake inhibitor (SNRI)
antidepressant. Specifically, the investigators hypothesize that symptoms potentially related
to deficient dopaminergic activity, such as lassitude, apathy, reduced positive affect and
impaired executive function, in particular, will improve. This protocol is designed to test
the hypothesis that this cluster of co-occurring residual symptoms sometimes found in treated
depression will respond as a group to adjunctive psychostimulant therapy. The investigators
propose to demonstrate this cluster of residual depressive symptoms and to measure the effect
of stimulant therapy on it. The investigators hope to better understand the specific symptoms
in this clinical population that are likely to improve with stimulant therapy.